US FDA approves Arrowhead's genetic disorder drug
18/11/2025 16:19
Nov 18 (Reuters) - The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals' ARWR.O drug for a type of genetic disorder that causes extremely high levels of fat in the bloodstream, the health regulator's website showed on Tuesday. (Reporting by Padmanabhan Ananthan and Christy Santhosh in Bengaluru; Editing by Tasim Zahid) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers